EWTX

Edgewise Therapeutics (EWTX) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.

Earnings

Edgewise Posts $1.17 Billion Quarterly Profit On Drug Sale, Operations Still Lose $46.1 Million

A $1.348 billion gain on selling sevasemten to Servier lifted third-quarter net income, and cash and securities reached about $1,743.9 million.

SEC Filings

Edgewise Books $1.35 Billion Gain On Sevasemten Sale Hours After Servier's Pivotal Trial Fails

Servier's Becker trial missed its goals a day before the filing, and none of the up to $1.1 billion in milestones sits in the gain.